Relapse after allogeneic hematopoietic cell transplantation (allo-HCT) for AML or myelodysplastic syndrome (MDS) remains the main cause of treatment failure, and is associated with a poor prognosis and short survival regardless of salvage therapy. 1 There are very few treatment modalities for this indication, including reduction/withdrawal of immunosuppressive therapy, chemotherapy with or without the infusion of donor lymphocytes, or a second allo-HCT, but results have been disappointing. 2, 3 Therefore, there is an unmet need for novel and more effective therapies. This also applies to the setting of prevention of relapse. Limited data exist regarding the efficacy of 5-azacytidine in the setting of post-allograft relapses. 4, 5 The data can be supported by experimental studies, showing that hypomethylating agents can induce functional suppressor function of regulatory T cells, mitigating GvHD without impairing GvL effect. 6 We hypothesized that early administration of low-dose 5-azacytidine after allo-HCT might help reduce relapse in patients with high-risk myeloid malignancies.
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The primary aim of our observational study was to evaluate the anti-leukemic effect of low-dose 5-azacytidine as a posttransplantation prophylactic therapy for relapse in patients with high-risk AML or MDS at the American university of Beirut Medical Center. Eighteen patients were enrolled, 13 had AML and 5 MDS. In our study, 13 patients (72%) received a risk-adapted intensity of busulfan at 130 mg/m 2 per day for either 2, 3 or 4 days, with a fixed dose of fludarabine (30 mg/m 2 per day for 5 days) and thymoglobulin (2.5 mg/kg per day for 2 days). Our algorithm was based on age, comorbidities and disease risk. 7 For GvHD prophylaxis, all patients received cyclosporine A (CsA, 3 mg/kg per day) initiated 3 days prior to hematopoietic stem cell infusion. The three haplo patients received 50 mg/kg post-transplant cyclophosphamide at days +3 and +5 after haplo-SCT with additional post-transplantation immunosuppressive agents (mycophenolate mofetil 500 mg × 4 per day and cyclosporine A 3 mg/kg per day were given starting on day +6). Mycophenolate mofetil was stopped at day +35, whereas CsA was progressively tapered from day +60 to day +100. All haplo patients received G-CSF starting on day +6.
All patients who underwent allo-HCT for MDS or AML were FLT3 negative. Donor lymphocyte infusion was not part of the treatment strategy. The clinical records of all patients were reviewed with reference to age, laboratory data, allo-HCT pertinent data, minimal residual disease, response to treatment and survival outcomes. This retrospective study was approved by the institutional review board of American university of Beirut Medical Center.
The disease risk index was intermediate in 9 (50%) patients, high in 4 (22%) and very high in 5 (28%). Nine patients (50%) had either a monosomal karyotype or a complex karyotype. 8 Eleven patients (61%) were in CR, 5 (28%) had residual disease and 2 patients (11%) had refractory acute leukemia. Fourteen patients (78%) received PBSC from HLA-identical siblings, 3 (17%) from haploidentical donors and 1 from a matched unrelated donor.
Patient and transplant characteristics are outlined in Table 1 . None of the patients experienced graft rejection. The median time to neutrophil engraftment was 16 days (range 12-20 days) and the median time to platelet engraftment was 10 days (range 0-34 days). Sixteen patients had at least one chimerism result by day 100 post allo-SCT. At days 30, 60, 100, complete (495%) donor chimerism was achieved by 15, 14 and 13 patients, respectively ( Figure 1 ).
Treatment with 5-azacytidine was started at a median of 60 (range: 39-111) days post transplant using a reduced dose of 32 mg/m 2 per day for 5 days monthly, for up to 5 years. All patients were in CR at the beginning of treatment. The discrepancy in time to start 5-azacitidine is attributed to approval by third-party payers. Patients received a median of 16 cycles (1-45). Three patients (17%) transiently discontinued their treatment, one for a duration of 3 months because of pneumonia, one for 6 months because of acute GvHD grade II and one for 2 weeks because of neutropenia. After a median follow-up of 19 months (3-60) from allo-HCT, 13 patients (72%) were still alive and 5 died; 3 from disease progression, 1 died because of CMV and JC virus infection, and 1 from a cardiac event. Of the 18 patients in our study, 5 patients (28%) developed ⩾ grade II acute GvHD. Of those patients, 3 (17%) and 2 (11%) had onset before and after starting 5-azacitidine, respectively. The median time to acute GvHD onset from transplant and 5-azacitidine are 64 days (range 34-107) and 39 days (range 38-59), respectively. At the last follow-up, 4 patients (22%) had chronic GvHD; (one limited and three extensive) ( Table 1) . None of the patients in our study discontinued GvHD prophylaxis before 5-azacitidine initiation. Finally, none of our patients permanently discontinued 5-azacitidine due to toxicity. Out of the 18 patients in our study, 6 (33%) developed probable toxicities related to 5-azacitidine after treatment initiation. Two patients (11%) developed neurological toxicities (blurry vision and peripheral neuropathy). One patient (5%) developed hemorrhagic cystitis. One patient (5%) developed both moderate neutropenia and cholestatic liver injury. One patient (5%) developed diarrhea and another (5%) developed non-viral hepatitis. In all six aforementioned patients, however, the toxicities in question were reversible without long-term sequelae (Table 1) .
All the 13 patients alive (72%) are in CR and have full donor chimerism. The 1-year disease-free survival and overall survival were 63% and 70%, respectively. The median disease-free survival and overall survival had not been reached at the time of this report ( Figure 2) .
Allo-HCT remains the only curative option for patients with high-risk AML and MDS. 9 The efficacy of transplantation is, however, in large part limited by regimen toxicity and GvHD, and most importantly, relapse. Accordingly, there remains an unmet need for better disease control and treatment of relapse after allografting. Data on 5-azacytidine use in this setting remain relatively anecdotal. There is no consensus regarding the appropriate dosing and duration of treatment with 5-azacytidine after allo-HCT. We prescribed the low dose of 32 mg/m receiving maintenance received varying doses of 5-azacytidine from 32 mg/m 2 , days 1-5, to 75 mg/m 2 , days 1-7. 5, 10 We observed lower rates of toxicity using the aforementioned dose of 5-azacytidine in our patients when compared to previous reports. Nevertheless, it must be emphasized that cytopenias and serious infections were not observed in a significant number of patients, as opposed to findings observed by others. 11, 12 In the study by de Lima et al., 5 higher doses of 5-azacytidine correlated with higher rates of toxicities during maintenance treatment. Conversely, in a recent study, with an update of the RICAZA study, Craddock et al. 13 demonstrated that 5-azacytidine is relatively well-tolerated after allo-HCT and appears capable of reducing the relapse risk in patients who demonstrate a CD8 + T-cell response to tumor Ags. In that study, 5-azacytidine was started on day +42 after allo-HCT, at a dose of 36 mg/m 2 subcutaneously, for 5 days on a 28-day schedule for up to 1 year. Interestingly, no patient developed extensive chronic GvHD. 13 Alternatively, in the study by Jabbour et al.,
10 low-dose 5-azacytidine was not only given as maintenance therapy, as is the case in our study, but also as salvage therapy for patients who had relapse post allo-HCT.
Our data need to be interpreted with caution owing to very small patient numbers. Intriguingly, despite the high risk of relapse in our patients (disease risk index at transplant, high or very high in 50% of patients), median disease-free survival and overall survival was not reached. We observed an encouraging overall survival of 70% at 1 year that compares favorably to Letter to the Editor previous reports. 4, 14 For instance, Schroeder et al. 15 reported 2-year survival of 19%, Czibere et al. 4 reported a 2-year survival of 23% and Tessoulin et al.
11 reported a 1-year survival of only 14%. We speculate that this difference in survival could be due in part to different time of survival analysis (that is, from allo-HCT in our study and from time of relapse diagnosis in others).
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In conclusion, low-dose 5-azacytidine used in a post-transplant preventive or maintenance setting until disease progression appears to be a promising intervention that can reduce the risk of relapse, and help maintain durable remissions in patients with high-risk AML or MDS. The toxicity related to this dose of 5-azacytidine is relatively low. Well-defined practice guidelines and large randomized controlled studies are certainly needed to establish the optimal timing, dose and treatment duration of 5-azacytidine post allo-HCT. Letter to the Editor
